Author: "Wanner C." / Publication Type: Conference Materials - Searchworks@Jio Institute Digital Library Search Results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Your search keyword '"Wanner C."' showing total 8 results

Start Over Author "Wanner C." Publication Type Conference Materials

8 results on '"Wanner C."'

1. Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME

Author: Kraus, BJ, additional, Weir, MR, additional, Bakris, GL, additional, Mattheus, M, additional, Cherney, DZI, additional, Sattar, N, additional, Heerspink, HJL, additional, Ritter, I, additional, von Eynatten, M, additional, Zinman, B, additional, Inzucchi, SE, additional, Wanner, C, additional, and Koitka-Webe, A, additional
Published: 2021
Full Text: View/download PDF

2. Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trial

Author: Inzucchi, SE, additional, Zinman, B, additional, Wanner, C, additional, Fitchett, D, additional, Anker, SD, additional, Pocock, S, additional, Kaspers, S, additional, George, JT, additional, Johansen, OE, additional, Jamal, W, additional, Hantel, S, additional, and Lund, SS, additional
Published: 2021
Full Text: View/download PDF

3. Empagliflozin reduces the total burden of cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial

Author: Fitchett, D, additional, Inzucchi, SE, additional, Zinman, B, additional, Wanner, C, additional, Anker, SD., additional, Pocock, S, additional, Kaspers, S, additional, George, JT, additional, Johansen, OE, additional, Jamal, W, additional, Hantel, S, additional, and Lund, SS, additional
Published: 2021
Full Text: View/download PDF

4. Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial

Author: Vaduganathan, M, additional, Sattar, N, additional, Fitchett, D, additional, George, JT, additional, Ofstad, AP, additional, Verma, S, additional, Mattheus, M, additional, Wanner, C, additional, Inzucchi, SE, additional, Zinman, B, additional, and Butler, J, additional
Published: 2021
Full Text: View/download PDF

5. Obstructive Sleep Apnoe and Cardiovascular, Heart Failure and Mortality Outcomes with Empagliflozin Versus Placebo in the EMPA-REG Outcome®Trial

Author: Yaggi, H.K., primary, Eliasson, B., additional, Kasai, T., additional, Marx, N., additional, Zinman, B., additional, Inzucchi, S.S.E., additional, Wanner, C., additional, Zwiener, I., additional, Wojeck, B., additional, Neeland, I.J., additional, and Johansen, O.E., additional
Published: 2020
Full Text: View/download PDF

6. Empagliflozin Improves Kidney Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol and HbA1c

Author: Wanner, C, additional, Cooper, M, additional, Inzucchi, S, additional, Zinman, B, additional, Zwiener, I, additional, Eynatten, M, additional, and Koitka-Weber, A, additional
Published: 2019
Full Text: View/download PDF

7. Composite retinopathy outcome in patients treated with empagliflozin versus placebo in the EMPA-REG OUTCOME trial

Author: Inzucchi, S, additional, Wanner, C, additional, Hehnke, U, additional, Lee, J, additional, Kaspers, S, additional, Clark, D, additional, George, J, additional, and Zinman, B, additional
Published: 2019
Full Text: View/download PDF

8. Reduction in cardiovascular death with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: Results from EMPA-REG OUTCOME

Author: Inzucchi, SE, additional, Fitchett, D, additional, Wanner, C, additional, George, J, additional, Woerle, HJ, additional, and Zinman, B, additional
Published: 2018
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results